Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1‐mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma

Ribonucleotide reductase (RR)M2B is an enzyme belonging to the ribonucleotide reductase enzyme family, which is essential for DNA synthesis and repair. RRM2B plays an important role in tumor progression and metastasis; however, little is known about the expression and underlying molecular mechanisms of RRM2B in hepatocellular carcinoma (HCC). In the present study, we report that down‐regulation of RRM2B in HCC is negatively associated with intrahepatic metastasis, regardless of p53 status. Moreover, the ectopic overexpression of RRM2B decreased HCC cell migration and invasion in vitro, whereas silencing RRM2B expression resulted in increased migration and invasion in vitro and intrahepatic and lung metastasis in vivo. Additionally, knockdown of RRM2B by short hairpin RNA (shRNA) in HCC cells was associated with epithelial‐mesenchymal transition (EMT), including the down‐regulation of E‐cadherin, and the concomitant up‐regulation of N‐cadherin and slug. A further experiment showed that RRM2B inhibited cell migration and spreading through regulation of the early growth response protein 1 (Egr‐1) / phosphatase and tensin homolog (PTEN) / Akt1 pathway. Consistently, we also detected a significant correlation between RRM2B and E‐cadherin protein expression in HCC tissues. Furthermore, Egr‐1 also directly bound to the RRM2B promoter and repressed RRM2B transcription, thereby establishing a negative regulatory feedback loop. Conclusion: These findings indicate that RRM2B suppresses cell migration and spreading by way of modulation of the Egr‐1/PTEN/Akt1 pathway. (Hepatology 2014;59:1459‐1470)

[1]  Rui Li,et al.  Slug promoted vasculogenic mimicry in hepatocellular carcinoma , 2013, Journal of cellular and molecular medicine.

[2]  Xi-jun Wang,et al.  Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma , 2013, Hepatology.

[3]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[4]  Boping Zhou,et al.  Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.

[5]  H. You,et al.  MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2 , 2012, Cell cycle.

[6]  R. Ballotti,et al.  The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion , 2012, PloS one.

[7]  Y. Yen,et al.  Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. , 2011, Anticancer research.

[8]  Ming Yao,et al.  Hypoxia‐inducible factor 1 alpha–activated angiopoietin‐like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule‐1/integrin β1 signaling in human hepatocellular carcinoma , 2011, Hepatology.

[9]  G. K. Chu,et al.  Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp‐1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance , 2011, Hepatology.

[10]  Lijun Xue,et al.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. , 2011, Cancer research.

[11]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[12]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[13]  Y. Yen,et al.  p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest , 2011, Molecular Cancer Therapeutics.

[14]  Lucila Ohno-Machado,et al.  Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. , 2011, Cancer research.

[15]  M. Fukayama,et al.  Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. , 2010, Human pathology.

[16]  Wei Gao,et al.  Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. , 2010, World journal of gastroenterology.

[17]  D. Gillespie,et al.  Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2 , 2010, The Journal of cell biology.

[18]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[19]  D. Calvisi,et al.  NORE1A tumor suppressor candidate modulates p21CIP1 via p53. , 2009, Cancer research.

[20]  H. You,et al.  Ribonucleotide reductase small subunit p53R2 suppresses MEK–ERK activity by binding to ERK kinase 2 , 2009, Oncogene.

[21]  S. Sheng,et al.  Metastasis and AKT activation , 2008, Cell cycle.

[22]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[23]  Anti-cancer Effects of JKA97 Are Associated with Its Induction of Cell Apoptosis via a Bax-dependent and p53-independent Pathway* , 2008, Journal of Biological Chemistry.

[24]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[25]  S. Natsugoe,et al.  Expression of p53R2 Is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[26]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[27]  K. Berns,et al.  Akt and 14-3-3η regulate Miz1 to control cell-cycle arrest after DNA damage , 2005, Nature Cell Biology.

[28]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[29]  E. Okamoto,et al.  Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel , 1996, Clinical & Experimental Metastasis.

[30]  Lijun Xue,et al.  The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. , 2003, Cancer research.

[31]  Yusuke Nakamura,et al.  Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools , 2003, Nature Genetics.

[32]  K. Sugimachi,et al.  Transcriptional repressor snail and progression of human hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  S. Chi,et al.  Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma , 2002, International journal of cancer.

[34]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[35]  T. Mustelin,et al.  The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling , 2001, Nature Cell Biology.

[36]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[37]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. , 1999, Cancer research.

[38]  U. Thorgeirsson,et al.  Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey , 1997, Hepatology.

[39]  S. Hirohashi,et al.  E‐cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma , 1996, Hepatology.